Three GLP-1s, liraglutide, semaglutide and dulaglutide, have now been approved to reduce the risks of cardiovascular disease. Several studies indicate GLP-1s may have even farther-ranging benefits.

Semaglutide, a common diabetes and weight loss medication, can have several long-term side effects. Despite this, experts generally consider it safe and effective.

Patients taking semaglutide, the active ingredient in Ozempic, were less likely to develop Alzheimer’s. Randomized clinical trials are needed to pin down the exact cause of this difference in risk.

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life improvements occurring despite minimal weight changes.

CHICAGO, June 21, 2025 /PRNewswire/ -- Today, a new analysis demonstrates the vascular benefits of semaglutide in patients with peripheral artery disease (PAD) and type 2 diabetes, including ...

Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities ...

Earlier this year, the FDA officially moved semaglutide, including popular versions like Ozempic and Wegovy, off of its drug shortage list, signaling the end of the condition which permitted ...

Longer Acting GLP-1 Receptor Agonists and the Potential for Improved Cardiovascular Outcomes A Review of Current Literature ...

By Vijay Kumar Malesu An important international trial shows that combining cagrilintide and semaglutide helps adults with obesity achieve more dramatic weight loss and better metabolic health ...